Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Tobira chairman’s dinner with Brent: Industry chat led to a 3-month pursuit and a stunning $1.7B deal
9 years ago
Deals
Soriot’s $3.5B Brilinta dream is dashed by yet another big trial flop for AstraZeneca
9 years ago
R&D
Summit shares rocket up, fueled by an $842M pact with Duchenne leader Sarepta
9 years ago
R&D
Korean officials launch Hanmi probe in wake of tox reports; Prothena CEO Schenk dies
9 years ago
News Briefing
Sun Pharma takes aim at a crowded market with another IL-23 psoriasis drug from Merck
9 years ago
R&D
Merrimack CEO is out as the biotech restructures, chopping its workforce and overhauling R&D
9 years ago
R&D
Pharma
$95M mega-round in hand, Elaine Sullivan sets out to build a European oncology player
9 years ago
R&D
AstraZeneca hands off another Amgen-partnered drug in a $1.5B deal with an acquisitive Allergan
9 years ago
R&D
Pharma
Presto! Wall Street magician Vivek Ramaswamy has another instant biotech IPO to sell you
9 years ago
People
Financing
J&J’s IL-23 star guselkumab grabs the spotlight in PhIII psoriasis showdown
9 years ago
R&D
Blockbuster performance: Regeneron, Sanofi add stellar PhIII dupilumab data on display at EADV
9 years ago
R&D
Following lethal tox report, Boehringer scraps plans for high-speed development, kills $730M Hanmi deal
9 years ago
R&D
Threshold blasted, restructures after a PhII failure; SQZ raises $16M
9 years ago
News Briefing
Week in review: Clinton over Trump; the hubs have it; we'll always have Paris
9 years ago
Bioregnum
Opinion
Scoop: Celgene targets a cure for myeloma/lymphoma with $600M EngMab buyout
9 years ago
Deals
In a setback, Regeneron reports a mid-stage flop for next-gen Eylea combo
9 years ago
R&D
ImmunoGen's new CEO retrenches, axing 65 staffers and looking to thin pipeline
9 years ago
R&D
Pharma
UCSF scientist rolls out a new blueprint for programming T cells, the 2.0 way
9 years ago
Startups
Catabasis shares rocket up on Duchenne pact with Sarepta; bluebird whistles up a TCR deal with Medigene
9 years ago
News Briefing
Amgen beefs up cardio pipeline, adding a $673M RNAi deal with Arrowhead
9 years ago
R&D
Step two: Celgene grabs a $20M option, plots MS PhII for Abide’s cannabinoid drug
9 years ago
R&D
Novo Nordisk takes out the ax and aims at R&D, chopping 1,000 jobs
9 years ago
R&D
Pharma
Genentech snares a PhI RAF inhibitor from Hanmi in $910M deal
9 years ago
R&D
Pharma
FDA slaps a full clinical hold on Alcobra’s troubled lead drug for ADHD, Fragile X
9 years ago
R&D
First page
Previous page
1161
1162
1163
1164
1165
1166
1167
Next page
Last page
Confirm Profile
Full Name
Email
Company
Job Title
{@!--CONSENT--!@}
Submit